-
公开(公告)号：US5672513A
公开(公告)日：1997-09-30
申请号：US217299
申请日：1994-03-23
Applicant: Alexey Terskikh , Andre Pelegrin , Jean-Pierre Mach
Inventor： Alexey Terskikh , Andre Pelegrin , Jean-Pierre Mach
IPC: A61K39/395 , C07K14/00 , C07K14/705 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/574 , C07K14/47 , C07K14/82
CPC classification number: C07K14/705 , Y10S530/828
Abstract: The present invention provides recombinant CEA glycoproteins and methods for their production. These recombinant CEA glycoproteins s lack the C-terminal 26 amino acids which are present in natural CEA and are characterized in that they are free from cross-reactive CEA-like antigens, antigenically indistingiushable from the soluble form of CEA shed from tumor cells, and devoid of the ethanolamine which is present at the C-terminus of natural CEA, and also devoid of the additional amino acids which may be attached to the natural CEA through said ethanolamine. Said recombinant CEA glycoproteins s preferably have the amino acid sequence SEQ ID NO: 1. The CEA glycoproteins s of the invention may be used as reagents in an immunoassay for the diagnosis of neoplastic diseases. The invention also relates to a DNA encoding said recombinant CEA glycoprotein, such as the DNA having the nucleotide sequence SEQ ID NO: 2 or a functional equivalent sequence thereof. The present invention also relates to recombinant vectors comprising said DNA, which recombinant vector is capable of directing the expression of said DNA in a compatible host cell, and to transformed host cells containing such a recombinant vector. The recombinant CEA glycoprotein of the present invention, preferably integrated in a test-kit, may be used for determining the presence of tumor cells in a sample of body fluid.
Abstract translation: 本发明提供重组CEA糖蛋白及其生产方法。 这些重组CEA糖蛋白缺乏存在于天然CEA中的C-末端26个氨基酸，其特征在于它们不具有从可溶形式从肿瘤细胞中流出的CEA抗原性不可抵抗的交叉反应性CEA-样抗原，以及 没有存在于天然CEA的C末端的乙醇胺，也没有可以通过所述乙醇胺与天然CEA连接的另外的氨基酸。 所述重组CEA糖蛋白优选具有SEQ ID NO：1的氨基酸序列。本发明的CEA糖蛋白可用作用于诊断肿瘤疾病的免疫测定中的试剂。 本发明还涉及编码所述重组CEA糖蛋白的DNA，例如具有核苷酸序列SEQ ID NO：2的DNA或其功能等同序列。 本发明还涉及包含所述DNA的重组载体，所述重组载体能够引导所述DNA在相容宿主细胞中的表达，以及含有这种重组载体的转化宿主细胞。 优选整合在试验盒中的本发明的重组CEA糖蛋白可用于测定体液样品中肿瘤细胞的存在。
-
公开(公告)号：US20100105876A1
公开(公告)日：2010-04-29
申请号：US10132533
申请日：2002-04-25
Applicant: Alexey Terskikh , Reto Crameri , Jean-Pierre Mach , Jean-Marc Le Doussal , Andrey Kajava
Inventor： Alexey Terskikh , Reto Crameri , Jean-Pierre Mach , Jean-Marc Le Doussal , Andrey Kajava
CPC classification number: C07K14/78 , C07K19/00 , C07K2319/00 , C07K2319/21 , C07K2319/73 , C12N15/62
Abstract: The present invention concerns an oligomer comprising more than 2 units, wherein each unit comprises a peptidic domain capable of oligomerizing and a domain capable of binding to an acceptor (ligand), wherein the oligomerizing domain is not an antibody or a functional antibody fragment from the constant region. Also described is the use and synthesis of this oligomer.
Abstract translation: 本发明涉及包含多于2个单元的寡聚体，其中每个单元包括能够低聚的肽结构域和能够结合受体（配体）的结构域，其中所述寡聚结构域不是抗体或功能性抗体片段 恒定区。 还描述了该低聚物的用途和合成。
-
公开(公告)号：US20060269540A1
公开(公告)日：2006-11-30
申请号：US10529221
申请日：2003-09-26
Applicant: Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
Inventor： Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
CPC classification number: C07K16/30 , C07K14/70539 , C07K2317/54 , C07K2317/55 , C07K2319/00
Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a β2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
Abstract translation: 本发明涉及包含一种或多种与特异于细胞表面标志物的抗体结合的CD1d复合物的化合物。 CD1d复合物包含CD1d，β2-微球蛋白分子，并且还可以包含与CD1d结合槽结合的抗原。 本发明进一步涉及用CD1d抗体化合物抑制或刺激免疫应答的方法，特别是抗肿瘤和自身免疫应答。
-
4.发明申请Compositions Comprising Fetal Hemoglobin and Bacterial Endotoxin and Optionally Additional Fetal Liver Components 有权组成包括胎儿血红蛋白和细菌内毒素和任选额外的胎肝组成公开(公告)号：US20080075742A1
公开(公告)日：2008-03-27
申请号：US10545500
申请日：2004-02-18
Applicant: Otto Westphal , Josette Mottier Westphal , Alexander Westphal , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
Inventor： Otto Westphal , Josette Mottier Westphal , Alexander Westphal , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
CPC classification number: A61K35/407 , A23L33/10 , A61K35/74 , A61K38/42 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the γ-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.
Abstract translation: 本发明涉及代表包含细菌内毒素，胎儿血红蛋白或更特别是不含血红素的衍生物或其γ链，以及任选地除了HbF之外存在于胎肝中的成分的新型免疫调节原理的药物组合物。 组合物以药学上可接受的载体和/或稀释剂递送给人。 根据本发明，惊奇地发现内毒素和胎儿血红蛋白部分结构显示出显着的协同生物医学活性。 胎儿血红蛋白及其部分结构的生物医学效应令人惊奇地不是基于作为氧转运蛋白的经典血红蛋白功能，而是与内毒素介导的生物活性的调节有关。 在口服施用组合物后，也观察到该生物医学活性。 本发明的组合物发现了各种各样的应用，其具有共同的刺激免疫系统的作用，并且从对Th1型反应的Th2导向反应的细胞因子和趋化因子的极化反转。 因此，提出的申请将包括治疗过敏性疾病，恶性肿瘤，慢性感染，自身免疫现象和年龄相关的不平衡。
-
公开(公告)号：US09631031B2
公开(公告)日：2017-04-25
申请号：US14130773
申请日：2012-07-06
Applicant: Jean Kadouche , Jean-Pierre Mach , Olivier Michielin , Vincent Zoete , Justyna Iwaszkiewicz , Martine Cerutti , Sylvie Choblet , Josee Golay
Inventor： Jean Kadouche , Jean-Pierre Mach , Olivier Michielin , Vincent Zoete , Justyna Iwaszkiewicz , Martine Cerutti , Sylvie Choblet , Josee Golay
CPC classification number: C07K16/468 , C07K16/2833 , C07K16/2896 , C07K2317/31 , C07K2317/522 , C07K2317/55 , C07K2317/732
Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.
-
Patent Agency Ranking
6.发明授权Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components 有权包含胎儿血红蛋白和细菌内毒素以及任选的额外的胎儿肝组分的组合物公开(公告)号：US07968103B2
公开(公告)日：2011-06-28
申请号：US10545500
申请日：2004-02-18
Applicant: Otto Westphal , Josette Westphal, legal representative , Alexander Westphal, legal representative , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
Inventor： Otto Westphal , Thierry Walli , Reginald Gorczynski , Silke Muller , Jean-Pierre Mach , Alfred Hartman , Wolfgang Bessler , Petra Hofmann , Ulrich Zahringer , Christian Alexander , Ulrich vor dem Esche , Artur J. Ulmer , Antonio Verdini
CPC classification number: A61K35/407 , A23L33/10 , A61K35/74 , A61K38/42 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the γ-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.
Abstract translation: 本发明涉及代表包含细菌内毒素，胎儿血红蛋白或更特别是不含血红素的衍生物或其γ-链以及除HbF之外存在于胎肝中的成分的新型免疫调节原理的药物组合物。 组合物以药学上可接受的载体和/或稀释剂递送给人。 根据本发明，惊奇地发现内毒素和胎儿血红蛋白部分结构显示出显着的协同生物医学活性。 胎儿血红蛋白及其部分结构的生物医学效应令人惊奇地不是基于作为氧转运蛋白的经典血红蛋白功能，而是与内毒素介导的生物活性的调节有关。 在口服施用组合物后，也观察到该生物医学活性。 本发明的组合物发现了各种各样的应用，其具有共同的刺激免疫系统的作用，并且从对Th1型反应的Th2导向反应的细胞因子和趋化因子的极化反转。 因此，提出的申请将包括治疗过敏性疾病，恶性肿瘤，慢性感染，自身免疫现象和年龄相关的不平衡。
-
7.发明授权Monoclonal antibodies with specificity affinity for human carcinoembryonic antigen 失效对人癌胚抗原具有特异性亲和力的单克隆抗体
公开(公告)号：US5047507A
公开(公告)日：1991-09-10
申请号：US293467
申请日：1989-01-04
Applicant: Franz Buchegger , Jean-Pierre Mach
Inventor： Franz Buchegger , Jean-Pierre Mach
IPC: G01N33/574 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/30 , C12N5/10 , C12N5/20 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/577
CPC classification number: C07K16/3007 , A61K38/00
Abstract: The invention concerns novel monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines secreting the antibodies, and processes for the preparation of said cell lines. The monoclonal antibodies of the invention and their derivatives are useful in the diagnosis and therapy of cancer and serial monitoring of cancer patients for recurrent disease or response to therapy. Test kits and pharmaceutical compositions containing said monoclonal anti-CEA antibodies are also subject of the invention.
-
8.发明申请Multicomponent conjugates which bind to target molecules and stimulate T cell lysis 审中-公开结合靶分子并刺激T细胞裂解的多组分缀合物公开(公告)号：US20070237771A1
公开(公告)日：2007-10-11
申请号：US11804945
申请日：2007-05-21
Applicant: Alena Donda , Jean-Pierre Mach , Valerie Cesson , Bruno Robert , Pedro Romero , Immanuel Leuscher , Philippe Guillaume
Inventor： Alena Donda , Jean-Pierre Mach , Valerie Cesson , Bruno Robert , Pedro Romero , Immanuel Leuscher , Philippe Guillaume
IPC: A61K39/395 , A61K38/16 , A61P35/00 , C07K14/00 , C07K16/00
CPC classification number: C07K16/3007 , A61K38/00 , A61K47/6811 , A61K47/6843 , A61K47/6849 , A61K47/6853 , A61K47/6855 , A61K47/6875 , A61K2039/505 , C07K16/2896 , C07K16/32 , C07K16/46 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2319/33
Abstract: The invention relates to immunoconjugates of formula: A-B—(C)n where B may be present or absent, A is a specific binding protein such as an antibody or an antibody binding fragment, or a ligand binding to a receptor present on target cells B comprises at least one molecule to which “A” and “C” bind, such as an avidin/streptavidin complex, “C” is an MHC molecule, and “n” is a whole number ranging from 1 to 10. The conjugates provide the exquisite binding specificity of antibodies, combined with an ability to stimulate cytotoxic T cells to identify and to destroy cells on which the conjugate is bound and oligomerized. The conjugates are useful both therapeutically and diagnostically.
Abstract translation: 本发明涉及下式的免疫缀合物：<？in-line-formula description =“In-line Formulas”end =“lead”？> AB-（C）
-
公开(公告)号：US20060233808A1
公开(公告)日：2006-10-19
申请号：US10551977
申请日：2004-04-05
Applicant: David Deperthes , Sylvain Cloutier , Jean-Pierre Mach , Nils Holler , Omar Fattah
Inventor： David Deperthes , Sylvain Cloutier , Jean-Pierre Mach , Nils Holler , Omar Fattah
IPC: A61K39/395 , G01N33/574 , C07H21/04 , C12P21/06 , C12N5/06 , C07K16/30 , C07K16/46
CPC classification number: C07K16/2863 , C07K14/485 , C07K14/78 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2319/21 , C07K2319/70 , C07K2319/73 , C12N15/62 , G01N33/57492
Abstract: The present invention relates to an isolated and recombinant fusion peptabody, which binds to a member of the epidermal growth factor receptor useful in inhibiting the growth of certain tumor cells. Also disclosed are, nucleic acids encoding said isolated and recombinant fusion peptabody, kits and pharmaceutical compositions comprising said isolated and recombinant fusion peptabody as an active substance. Finally, a method for the manufacture of said isolated and recombinant fusion peptabody, and its use for the preparation of a medicament for the treatment or prevention of cancer are provided.
Abstract translation: 本发明涉及分离和重组的融合肽抗生素，其结合用于抑制某些肿瘤细胞生长的表皮生长因子受体的成员。 还公开了编码所述分离和重组融合肽抗体的核酸，试剂盒和药物组合物，其包含所述分离和重组融合肽抗体作为活性物质。 最后，提供了用于制备所述分离和重组融合肽抗体的方法及其用于制备用于治疗或预防癌症的药物的用途。
-
公开(公告)号：US09809654B2
公开(公告)日：2017-11-07
申请号：US10529221
申请日：2003-09-26
Applicant: Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
Inventor： Bruno Robert , Alena Donda , Valerie Cesson , Jean-Pierre Mach , Maurice Zauderer
CPC classification number: C07K16/30 , C07K14/70539 , C07K2317/54 , C07K2317/55 , C07K2319/00
Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a β2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.033 seconds)
